Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus CE for ED-SCLC
NCT03382561Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2018
- Primary completion
- Feb 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab in small cell lung cancer (SCLC) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Progression-Free Survival. Started May 2018; status: completed.
02
Drugs
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03382561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03382561.